<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01528800</url>
  </required_header>
  <id_info>
    <org_study_id>iPACK-HD</org_study_id>
    <nct_id>NCT01528800</nct_id>
  </id_info>
  <brief_title>Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients</brief_title>
  <acronym>iPACK-HD</acronym>
  <official_title>Inhibit Progression of Coronary Artery Calcification With Vitamin K in HemoDialysis Patients: The iPACK-HD Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Rachel Holden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Evaluation Research Unit at Kingston General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if vitamin K supplementation three times per week reduces
      the progression of coronary artery calcification over 12 months in dialysis patients compared
      to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At every stage of chronic kidney disease (CKD), the leading cause of mortality is
      cardiovascular disease. This is due, in part, to vascular calcification (VC) of the coronary
      arteries. The extent of VC in the coronary arteries of patients with CKD is commonly
      determined by high resolution CT scan. The total coronary artery calcium (CAC) score,
      measured in Agatston units (AUs), reflects the calcium burden in the three major coronary
      arteries and is the current standard for determining extent of vascular calcification in
      hemodialysis patients. Matrix Gla protein (MGP), a vitamin K dependent protein, is a key
      inhibitor of vascular calcification and is present in the arterial wall. It is established
      that MGP becomes up-regulated adjacent to sites of calcification and that vitamin K is
      critical to its function. Therefore vitamin K status may be critical to the extent of
      vascular calcification in this patient group. However, to date, no trial has examined whether
      vitamin K supplementation prevents the progression of coronary artery calcification in
      patients with kidney failure, a group in which high risk has been established. Therefore, our
      primary research question is: Does vitamin K supplementation with 10 mg of phylloquinone
      thrice weekly reduce the progression of coronary artery calcification (as measured by CAC
      score) over 12 months in prevalent hemodialysis patients with a baseline CAC score of â‰¥ 30
      Agatston Units compared to placebo?
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment rate</measure>
    <time_frame>12 months</time_frame>
    <description>i.e. Number of participants recruited per month.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance with study medication</measure>
    <time_frame>12 months</time_frame>
    <description>i.e. Proportion of prescribed doses received.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dropout rate</measure>
    <time_frame>12 months</time_frame>
    <description>i.e. Number of participants who drop out from the trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to study protocol</measure>
    <time_frame>12 months</time_frame>
    <description>i.e. Proportion of participants who adhere to the study protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electronic data capture system form completion</measure>
    <time_frame>12 months</time_frame>
    <description>i.e. Proportion of required electronic data capture system forms completed successfully.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coronary artery calcification (Agatston calcium scores) progression</measure>
    <time_frame>12 months</time_frame>
    <description>Agatston calcium scores (CT scans) will be measured at baseline and at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary artery calcification (volume calcium scores) progression</measure>
    <time_frame>12 months</time_frame>
    <description>Volume calcium scores (CT scans) will be measured at baseline and at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence and incidence of thoracic vertebral fractures</measure>
    <time_frame>12 months</time_frame>
    <description>Radiographs of the thoracic spine will be assessed at baseline and at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence and incidence of lumbar vertebral fractures</measure>
    <time_frame>12 months</time_frame>
    <description>Radiographs of the lumbar spine will be assessed at baseline and at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>12 months</time_frame>
    <description>Acute coronary syndrome, congestive heart failure, myocardial infarction, stroke, transient ischemic attack, amputation; cardiac, (symptom-driven) cerebral or peripheral revascularization procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>Deep vein thrombosis and pulmonary embolism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HD access thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>Fistula and/or graft thrombosis or dialysis catheter thrombosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months</time_frame>
    <description>All-cause and cardiovascular cause .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phylloquinone</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PIVKA</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MGP</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desphospho-carboxylated matrix Gla protein (dpcMGP)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desphospho-uncarboxylated matrix Gla protein (dpucMGP)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thoracic aortic calcification (absolute change of Agatston calcium scores) progression</measure>
    <time_frame>12 months</time_frame>
    <description>The absolute change of the Agatston calcium scores (CT scan) will be assessed at 12 months vs. baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thoracic aortic calcification (absolute change of volume calcium scores) progression</measure>
    <time_frame>12 months</time_frame>
    <description>The absolute change of the volume calcium scores (CT scan) will be assessed at 12 months vs. baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic valve calcification (absolute change of Agatston calcium scores) progression</measure>
    <time_frame>12 months</time_frame>
    <description>The absolute change of the Agatston calcium scores (CT scan) will be assessed at 12 months vs. baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic valve calcification (absolute change of volume calcium scores) progression</measure>
    <time_frame>12 months</time_frame>
    <description>The absolute change of the volume calcium scores (CT scan) will be assessed at 12 months vs. baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral valve calcification (absolute change of Agatston calcium scores) progression</measure>
    <time_frame>12 months</time_frame>
    <description>The absolute change of the Agatston calcium scores (CT scan) will be assessed at 12 months vs. baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral valve calcification (absolute change of volume calcium scores) progression</measure>
    <time_frame>12 months</time_frame>
    <description>The absolute change of the volume calcium scores (CT scan) will be assessed at 12 months vs. baseline.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Interleukin 6 (IL-6)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Fetuin</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Osteoprotegerin</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Phosphorus</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Calcium</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Parathyroid hormone (PTH)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dosage of phosphorus binders</measure>
    <time_frame>12 months</time_frame>
    <description>i.e. Calcium carbonate, calcium acetate, TUMS, sevelamer, Lanthanum, Sucralfate).</description>
  </other_outcome>
  <other_outcome>
    <measure>Dosage of ergo-calciferol (25(OH) vitamin D)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dosage of vitamin D analogues</measure>
    <time_frame>12 months</time_frame>
    <description>i.e. Calcitriol, paricalcitol.</description>
  </other_outcome>
  <other_outcome>
    <measure>Dosage of lipid lowering medications</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dosage of angiotensin converting enzyme inhibitors</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dosage of angiotensin receptor blockers</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dosage of antihypertensives</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dosage of multivitamins</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dosage of bisphosphonates</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dosage of prednisone</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dosage of cholesterol-lowering medications</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in L3 slice muscle cross-sectional area</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in L3 slice normalized muscle cross-sectional area</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in L3 slice intermuscular adipose tissue (IMAT) cross-sectional area</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in L3 slice visceral adipose tissue (VAT) cross-sectional area</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in L3 slice subcutaneous adipose tissue (SAT) cross-sectional area</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in L3 slice total adipose tissue (TAT) cross-sectional area</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in L3 slice muscle radiodensity</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in L3 slice intermuscular adipose tissue (IMAT) radiodensity</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in L3 slice visceral adipose tissue (VAT) radiodensity</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in L3 slice subcutaneous adipose tissue (SAT) radiodensity</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Thoracic aortic calcification (Agatston score) progression</measure>
    <time_frame>12 months</time_frame>
    <description>Percent of patients with regression of thoracic aortic calcification of at least 10% (Agatston score) will be assessed at 12 months compared to the baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Thoracic aortic calcification (volume) progression</measure>
    <time_frame>12 months</time_frame>
    <description>Percent of patients with regression of thoracic aortic calcification of at least 10% (volume) will be assessed at 12 months compared to the baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Coronary artery calcification (Agatston score) progression</measure>
    <time_frame>12 months</time_frame>
    <description>Percent of patients with regression of coronary artery calcification (Agatston score) of at least 10% will be assessed at 12 months compared to the baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Coronary artery calcification (volume) progression</measure>
    <time_frame>12 months</time_frame>
    <description>Percent of patients with regression of coronary artery calcification (volume) of at least 10% will be assessed at 12 months compared to the baseline.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>End-stage Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microcrystalline Methylcellulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin K1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin K1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin K1</intervention_name>
    <description>10mg orally three times a week for 12 months</description>
    <arm_group_label>Vitamin K1</arm_group_label>
    <other_name>Phytonadione</other_name>
    <other_name>Phylloquinone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microcrystalline Methylcellulose</intervention_name>
    <description>10mg orally three times a week for 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide signed informed consent

          -  â‰¥18 years of age

          -  Expected to survive one year

          -  Have end-stage kidney disease and require hemodialysis

          -  Have a baseline coronary artery calcification score â‰¥30 Agatston units (AUs)

        Exclusion Criteria:

          -  Have a medical condition that requires warfarin

          -  Require hemodialysis for acute kidney injury

          -  Are Pregnant

          -  Have other severe co-morbid conditions (e.g. malignancy, disabling stroke) with life
             expectancy less than one year

          -  Have undergone coronary artery bypass grafting or have stents placed in their coronary
             arteries

          -  Are currently enrolled in another interventional trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Holden</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queens University/Kingston Health Sciences Centre: Kingston General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre: Kingston General Hospital Site</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 6, 2012</study_first_submitted>
  <study_first_submitted_qc>February 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2012</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Evaluation Research Unit at Kingston General Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Rachel Holden</investigator_full_name>
    <investigator_title>Professor of Medicine Queen's University</investigator_title>
  </responsible_party>
  <keyword>Vitamin K</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Vascular Calcification</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Coronary Artery Calcification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

